Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Mersana Raises Cash, Teams With Adimab

by Lisa M. Jarvis
August 6, 2012 | A version of this story appeared in Volume 90, Issue 32

Mersana Therapeutics has raised $27 million in a round of financing led by New Enterprise Associates, a new investor in the biotech firm. Pfizer Venture Investments is also a new investor in the financing round, which will help Mersana develop antibody-drug conjugates (ADCs). Separately, Mersana has teamed with Adimab to offer integrated antibody discovery and ADC technology. Adimab will optimize antibodies for use with Mersana’s Fleximer polymer and linker technology.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.